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The entry of the coronavirus SARS-CoV-2 into human lung cells can be inhibited by the approved drugs
camostat and nafamostat. Here we elucidate the molecular mechanism of these drugs by combining
experiments and simulations. In vitro assays confirm that both drugs inhibit the human protein TMPRSS2,
a SARS-Cov-2 spike protein activator. As no experimental structure is available, we provide a model of
the TMPRSS2 equilibrium structure and its fluctuations by relaxing an initial homology structure with
extensive 330 microseconds of all-atom molecular dynamics (MD) and Markov modeling. Through
Markov modeling, we describe the binding process of both drugs and a metabolic product of camostat
(GBPA) to TMPRSS2, reaching a Michaelis complex (MC) state, which precedes the formation of a long-
lived covalent inhibitory state. We find that nafamostat has a higher MC population than camostat and
GBPA, suggesting that nafamostat is more readily available to form the stable covalent enzyme–
substrate intermediate, effectively explaining its high potency. This model is backed by our in vitro
experiments and consistent with previous virus cell entry assays. Our TMPRSS2–drug structures are
made public to guide the design of more potent and specific inhibitors.1 Introduction
In December 2019 several cases of unusual and severe pneu-
monia were reported in the city of Wuhan, China. These cases
were traced back to a new coronavirus, SARS-CoV-2 (severe acute
respiratory syndrome coronavirus 2); the disease is called
COVID-19.1 As of October 11, 2020 there are over 37 million
conrmed COVID-19 cases and more than 1 million deaths,2
with both numbers likely to be severe underestimates. Giventhematics and Computer Science, Berlin,
sics, Berlin, Germany
nati Children's Hospital Medical Center,
cinnati College of Medicine, Cincinnati,
cinnati College of Medicine, Cincinnati,
Center – Leibniz Institute for Primate
ty Göttingen, Göttingen, Germany
ouston, TX, USA
epartment of Computer Science and
tion (ESI) available. See DOI:
the Royal Society of Chemistryestimates of the infection mortality rate of 0.4 to 1.4% (ref. 3–5)
the virus has the potential to kill tens of millions of people
unless efficient vaccines or drugs are available.
As other coronaviruses,6–9 SARS-CoV-2 exploits host proteins
to initiate cell-entry, in particular TMPRSS2 and ACE2, two
membrane-bound proteins expressed in the upper and lower
respiratory tract.10–13 TMPRSS2 contains an extracellular trypsin-
like serine-protease domain that can proteolytically activate the
spike (S) protein on the surface of SARS-CoV-2 viral particles14
(Fig. 1). While in certain cell lines, the S-protein can also be
activated by the endo/lysosomal pH-dependent cysteine
protease cathepsin L,14,15 virus entry into human airway cells14,16
seems to depend on TMPRSS2 but not cathepsin L. Consis-
tently, epidemiological data of prostate cancer patientsFig. 1 Overview of viral entry mechanism.
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Fig. 2 (A) Chemical structure of nafamostat (magenta), camostat
(blue), and GBPA (orange), split in a common moiety (4-guanidino-
benzoyl) and different leaving groups. Note that GBPA is the hydro-
lyzed version of camostat's leaving group ester. (B) General
mechanism of serine proteases applied to the hydrolysis of 4-guani-
dinobenzoyl esters by TMPRSS2. Only H296 and S441 residues of the
catalytic triad and the two backbone NH groups of the oxyanion hole
are depicted for clarity (enzyme color coded in green). (C) Dose
response behavior of TMPRSS2 inhibition by nafamostat (magenta) and
camostat (blue) with IC50s (data normalized, background subtracted).
Experimental enzyme activities are reported at different drug
concentrations as mean and standard deviation across independent
experiments, continuous lines depict fitted dose–response model
used for IC50 computation.




















































View Article Onlineundergoing androgen-deprivation therapies, which lowers
TMPRSS2 levels, indicate a lower risk of contracting the SARS-
CoV-2 infection.17 We further note that low concentration
levels of TMPRSS2 are observed in children and infants,
possibly explaining lower risks of severe COVID-19 infections in
younger age groups.18
TMPRSS2 is also exploited by other coronaviruses and
inuenza A viruses for activation of surface glycoproteins, viral
spread, and pathogenesis.19–25 TMPRSS2 knock-out mice have
no phenotype in the absence of infection,26 indicating that
inhibiting TMPRSS2 function might not be associated with
substantial unwanted side effects. As a result, TMPRSS2 is
a promising therapeutic target in the context of inuenza A and
coronavirus infection, including SARS-CoV-2. Since TMPRSS2 is
host encoded and thus genetically stable, treatment should be
associated with a low risk of drug resistance.
Here, we study the structural basis and molecular mecha-
nism of TMPRSS2 inhibition by nafamostat, camostat, and its
metabolic product 4-(4-guanidinobenzoyloxy)phenylacetic acid
(GBPA). These guanidinobenzoyl-containing drugs are
approved for human use in Japan and have been demonstrated
to inhibit SARS-CoV-2 cell-entry.14,27–29 A recent survey of FDA
approved drugs further found nafamostat to be an effective
inhibitor of SARS-Cov-2 infection in human lung-cell cultures.30
We report experimental measurements demonstrating that
nafamostat and camostat inhibit TMPRSS2 activity by using our
recently established cell-based assay,31 consistent with in vitro
enzymatic TMPRSS2 activity assays.32
Despite the hopes associated with TMPRSS2 inhibition, we
are, as yet, lacking an experimental structure. We here go
beyond the previous dependence on homology models by an
extensive 330 microseconds of high-throughput all-atom
molecular dynamics (MD) simulations and Markov modeling.
This approach provides an ensemble of equilibrium structures
of the protein–drug complex and also drug binding kinetics. We
show that nafamostat, camostat, and GBPA are covalent
inhibitors with an identical covalent complex, but their
different inhibitory activity can be explained by different pop-
ulations of their Michaelis complex preceding the covalent
complex. These ndings, combined with the simulation struc-
tures that we make publicly available, provide an important
basis for developing more potent and specic TMPRSS2
inhibitors.
2 Results
Camostat and nafamostat inhibit the catalytic activity of
TMPRSS2
First we conrm that camostat and nafamostat are TMPRSS2
inhibitors. To this end, we employ our recently reported activity
assay31 of the full-length TMPRSS2 protein on the surface of live
cells with both inhibitors (Fig. 2A). Briey, we transfected the
human cell-line HEK-293T with a TMPRSS2 expression vector.
We then measured the protease activity of the transfected cells
using the uorogenic peptide substrate BOC-QAR-AMC,
following incubation of the cell with increasing inhibitor
concentrations. Peptide-digestion induced a minimal increase984 | Chem. Sci., 2021, 12, 983–992in uorescent signal in control cells without exogenous
TMPRSS2 expression (un-normalized mean enzyme activity ¼
2.4), while TMPRSS2 over-expression resulted in a much faster
peptide digestion (un-normalized mean enzyme activity¼ 12.8).
Therefore, our assay is mostly specic for TMPRSS2.31 Signi-
cantly lower enzyme activity at higher drug concentrations can
thus be attributed to TMPRSS2 inhibition.
For both camostat and nafamostat, we see a clear dose-
dependent inhibition and estimate their respective IC50© 2021 The Author(s). Published by the Royal Society of Chemistry




















































View Article Onlinevalues to 142  31 nM and 55  7 nM (Fig. 2C). Our results are
consistent with the nding that both drugs inhibit cell entry of
SARS-CoV-2 and other coronaviruses, and that nafamostat is the
most potent inhibitor.27,28,32
Note that in humans, camostat is rapidly processed to 4-(4-
guanidinobenzoyloxy)phenylacetic acid (GBPA) (Fig. 2A).33 It
has been recently shown that GBPA also inhibits TMPRSS2 and
cell entry of SARS-CoV-2 viruses, although slightly less effi-
ciently than camostat.29 Hence, we subsequently study the
molecular interactions between TMPRSS2 and all three
compounds: camostat, GBPA, and nafamostat.Equilibrium structures of TMPRSS2 in complex with camostat
and nafamostat
We now set off to investigate the molecular mechanism of
TMPRSS2 inhibition by nafamostat, camostat, and its metabo-
lite GBPA. No TMPRSS2 crystal structure is available to date,
however it has been shown that all-atom MD simulations can
reliably model the equilibrium structures of proteins when (i)
a reasonable model is available as starting structure, and (ii)
simulations sample extensively, such that deciencies of the
starting structure can be overcome.35–39
Here, we initialize our simulations with recent homology
models of the TMPRSS2 protease domain and with camostat/
nafamostat docked to them.40 Trypsins adopt a common fold
and share an active-site charge relay system whose structuralFig. 3 TMPRSS2 structure and Michaelis complex with camostat, its me
catalytic domain of TMPRSS2. Protein flexibility is shown by cyan halo, ca
example of trypsin peptide recognition (PDB ID 4Y0Y,34 peptide displaye
and nafamostat (E and F) in complex with TMPRSS2. All drugs (yellow lico
their guanidinium heads interacting with D435, while (F) shows a reverse
Markov model simulations of minimal distance to D435 (at the S1 poc
trajectory is in MC state, red) for camostat (G), GBPA (H), and nafamosta
© 2021 The Author(s). Published by the Royal Society of Chemistryrequirements for catalytic activity are well understood;41 we
select our MD model consistent with these structural require-
ments. In particular, we focus on systems with Asp435
(substrate recognition) deprotonated and His296 (catalytic
function) in a neutral form (Nd protonated), as well as on the
interactions of a charged lysine nearby the catalytic Asp345
(Fig. S1 and S2†).
In order to avoid artifacts of the initial structural model and
to simulate the equilibrium ensemble of the TMPRSS2–drug
complexes, we collected a total of 100 ms of simulation data for
TMPRSS2–camostat, 50ms for TMPRSS2–GBPA, and 180 ms for
TMPRSS2–nafamostat. Every drug dataset has converged RMSD
distributions (Fig. S5†) and samples various drug poses and
multiple association/dissociation events. Using Markov
modeling42–46 we derive the structures of the long-lived (meta-
stable) states and characterize protein–drug binding kinetics
and thermodynamics.
We nd TMPRSS2 has exible loops around the binding site
but maintains stable structural features shared by other trypsin-
like proteases (Fig. 3A and S6†). Aer formation of a non-
covalent substrate–enzyme complex (binding step, Fig. 2B),
trypsins cleave peptide-like bonds in two catalytic steps, assis-
ted by a conserved catalytic triad (Asp345, His296, and Ser441 in
TMPRSS2). The rst step involves the formation of a covalent
acyl–enzyme intermediate between the substrate and Ser441.41
During this step, His296 serves as a general base to deprotonatetabolic product GBPA, and nafamostat. (A) Active site overview of the
talytic triad is shown in black. (B) Pre-catalytic binding mode shown at
d in white). (C–F) Representative structures of camostat (C), GBPA (D),
rice representation) bind into the S1 pocket of TMPRSS2, in (C–E) with
binding mode with nafamostat binding with its aminidinium head. (G–I)
ket, blue), reactivity coordinate (black), and reactivity state (i.e. when
t (I).
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View Article Onlinethe nucleophilic Ser441, and subsequently as a general acid to
protonate the leaving group of the substrate. The second step
involves the hydrolysis of the acyl–enzyme intermediate,
releasing the cleaved substrate and restoring the active form of
the enzyme (Fig. 2B).
Along these two steps, the so called “oxyanion hole”, formed
by the backbone NHs of Gly439 and Ser441, helps to activate
and stabilize the carbonyl of the scissile bond. Another impor-
tant structural feature is the S1 pocket, which contains a well
conserved aspartate (Asp435) that is essential for substrate
binding and recognition. At the opposite site of the S1 pocket,
a loop containing a hydrophobic patch delimits the binding
region of substrates within enzymatic active site. All these
structural elements, known to play crucial roles in the function
of serine proteases,41 are generally stable and preserved in our
equilibrium structures (cf. Fig. S2 and S6†).Structural basis of TMPRSS2 inhibition by camostat and
nafamostat
Drugs with a guanidinobenzoyl moiety can inhibit trypsins by
mimicking their natural substrates (Fig. 3B). Indeed, the ester
group, resembling a peptide bond, can react with the catalytic
serine with rates that are orders of magnitude faster,47 forming
the acyl–enzyme intermediate. In contrast to peptide catalysis,
the drug's guanidinobenzoyl group stays covalently linked to
the catalytic serine with a small off-rate, rendering it an effective
chemical inhibitor.48 Note that in its inhibited state, the
TMPRSS2 active site is modied such that protease activity is
disabled, preventing SARS-CoV-2 S-protein cleavage.
The present MD simulations sample different conformations
of the complex formed by the enzyme with each of the drugs
that precede the covalent substrate–enzyme complex. We can,
therefore, elucidate their binding and how specic interactions
stabilize different modes. However, please note that our simu-
lations do not simulate the covalent complex's formation. All
binding modes mimic interactions made between trypsins and
their natural substrates, in which lysine heads interact with
a conserved aspartate in the S1 pocket (Asp435, Fig. 3B). In
camostat, its metabolic product GPBA, and nafamostat, the role
of the lysine heads is taken by the guanidinium heads which
bind in the S1 pocket and also interact with Asp435 (Fig. 3C–E).
However, the guanidinium–Asp435 salt bridge is formed and
broken transiently especially for camostat and GBPA (Fig. 3G–I),
indicating that these drugs are not optimized for the TMPRSS2
pocket (Fig. S4†).
Nafamostat also binds in a “reverse” orientation where the
amidinium head binds into the S1 pocket and interacts with
Asp435 (Fig. 3F).40 In this orientation, the guanidinium head
mainly interacts with Glu299, with the drug reactive center
slightly displaced from the oxyanion hole, while the “forward”
orientation (Fig. 3E) keeps the amidinium head mainly nearby
Val280, with the ester center well positioned for the reaction
(Fig. S3†). This observation is in agreement with several crystal
structures of acyl–enzyme intermediates between different
trypsins and guanidinobenzoyl molecules bound to the S1
pocket (e.g. PDBs 2AH4,49 3DFL,50 1GBT51). There are also986 | Chem. Sci., 2021, 12, 983–992“inverse substrates” known to react with rates comparable to
the ones of normal esters, suggesting that the inverted nafa-
mostat orientation may also be reactive.41
A fraction of the bound-state structures resembles a reactive
Michaelis complex (MC) which fullls the necessary criteria for
catalysis of the inhibitory acyl–enzyme complex: small distances
of (i) the drug ester carbon to catalytic serine oxygen, and (ii) the
catalytic serine hydrogen to catalytic histidine nitrogen
(Methods). We observe that besides Asp435 binding to the S1
pocket, drugs in the MC state are particularly stabilized by the
oxyanion hole. Our model predicts that nafamostat has the
highest MC state population followed by camostat and GBPA
(Fig. 4), an order that coincides with the one of experimental
drug binding affinities.29 We note that the relative free energies
of binding to the MC states are signicantly different between
nafamostat (2.1  0.1 kcal mol1) and the other drugs (2.8 
0.1 kcal mol1 and 3.1 0.2 kcal mol1 for camostat and GBPA,
respectively), with the bootstrap sample distributions of camo-
stat and its metabolite displaying a partial overlap.
Whereas the contact patterns of camostat and nafamostat
associated states are similar, the leaving group in the inverted
nafamostat conformation shows contacts predominantly with
residues E299 and Tyr337 (Fig. S3†). GBPA, due to its shorter
length, has less contacts to residues outside of the S1 pocket. In
the reactive MC state, interestingly, all tested drugs display
similar contact patterns overall, and their leaving groups bind
in between Val280 and His296, with their ester group in contact
with Ser441 (Fig. S3†).Kinetic mechanism of TMPRSS2 inhibition by camostat,
GBPA, and nafamostat
Finally, we investigate the molecular basis for the greater inhi-
bition by nafamostat and formulate starting points for
designing new and more efficient covalent TMPRSS2 inhibitors
following these leads.
To illustrate the reversible binding of camostat, its product
GBPA, and nafamostat to TMPRSS2, we used our Markov
models to simulate long time-scale trajectories of 50 ms (Fig. 3G–
I). We see a clear correlation between tight inhibitor–Asp435
interactions and contact formation between catalytic serine and
the inhibitor ester group, potentially forming a reactive
complex. In other words, the binding of reactive drugs in the S1
pocket favors the interactions necessary for a catalytically
competent MC.
We estimate the dissociation constants for the non-covalent
complex, i.e. the ratio of dissociated state and non-covalent
complex populations, to be between 6 and 9 mM for the three
drugs. Even though our IC50-measurements include other
processes and thus are not straightforward to compare, IC50-
values in the 10–100s nanomolar range (i.e. 4–5 orders of
magnitude smaller, Fig. 2C) are a strong indicator that the
major source of inhibition cannot be the non-covalent complex,
but is rather the longer-lived covalent acyl–enzyme complex.
However, as all three drugs yield identical acyl–enzyme
complexes, the differences in TMPRSS2 inhibition can only© 2021 The Author(s). Published by the Royal Society of Chemistry
Fig. 4 Binding kinetics model of camostat (top), camostat metabolic product GBPA (middle), and nafamostat (bottom). Inhibition process is
depicted from left (apo state) to right (covalent complex). Single representative structures for each intermediate state are shown – note that all
states have significant flexibility. Drugs are depicted in yellow, catalytic triad residues in black, leaving groups and covalent group are denoted by
LG and CG, respectively. Rates and populations predicted by our model are annotated at reaction arrows and states, respectively. The covalent
complex is illustrated using a structure with prostatin (PDB 3DFL50).




















































View Article Onlinearise from either (1) the formation or population of their MCs,
or (2) differences in the catalytic rate kcat of acylation.
Interestingly, we observe that the MSM-predicted pop-
ulations of the MCs in nafamostat, camostat, and GBPA have
approximate ratios of 6 : 2 : 1, respectively, as well as a signi-
cantly higher on-rate for nafamostat (Fig. 4). A simple three-
state kinetic model of dissociated state, MC and covalent
complex shows that the overall association constant (Ka, ratio of
inhibited versus apo protein states) directly scales with the
association constant of the MC (KMa , ratio of MC versus disso-





Simply speaking, this indicates that nafamostat is a better
inhibitor because it is more oen found in the reactive MC
state, and is therefore more likely to be attacked by the catalytic
serine oxygen and enter the long-lived acyl–enzyme inhibitor
complex.
Moreover, we note that the kcat of acylation of these drugs
may depend on their leaving group pKa's. Leaving groups with
a low pKa will require less assistance from acid catalysis and will
be easily displaced by the nucleophilic serine, favoring the© 2021 The Author(s). Published by the Royal Society of Chemistryformation of the acyl–enzyme intermediate. We expect the
leaving group of nafamostat to have a lower pKa than the one of
camostat, following the values of similar molecules such as
naphthol (9.57 (ref. 52)) and 4-methylphenol (10.26 (ref. 53)),
respectively. Indeed, these comparative insights are backed by
computational pKa predictions for nafamostat (9.17), camostat
(9.36), and GBPA (10.02) (Fig. S4†). We note that these predic-
tions are made in aqueous solution, which could differ slightly
from the estimates in the enzyme due to the different envi-
ronment. Nonetheless, we expect the pKa values to be in the
same relative order given that the three compounds have
similar contacts with the enzyme in the reactive state (Fig. S3†).
This suggests that the kcat of acylation will be slightly faster for
nafamostat in particular compared to the camostat metabolic
product GBPA, further contributing to nafamostat's superior
inhibition of TMPRSS2.
3 Discussion
Camostat and nafamostat are promising drug candidates for
a COVID-19 treatment strategy. Here we have combined cell-
based assays, extensive molecular simulations, and Markov
modeling to unravel the molecular action principle of these
drugs and provide data that may help to improve them further.Chem. Sci., 2021, 12, 983–992 | 987




















































View Article OnlineOur binding assays provide evidence that both inhibitors
directly act on TMPRSS2 and that nafamostat is more potent
compared to camostat, and this qualitative difference is in
agreement with complementary in vitro assays on puried
protein construct32 or cell-entry assays.27,28 We note that the
absolute IC50 values differ between these three assay types,
reecting differences in experimental conditions and which
function is being inhibited and measured.
While no crystallographic structure of TMPRSS2 is available,
we provide extensive 330 microseconds of all-atom MD simu-
lations starting from a homology model that generate stable
equilibrium structure ensembles of the protein–drug
complexes. These simulations sample multiple association/
dissociation events and various drug poses in the protein
active site. Our analyses show that the non-covalent complexes
of nafamostat, camostat, and its metabolic product GBPA are
relatively short-lived, suggesting that the main inhibitory effect
is due to the formation of the long-lived covalent acyl–enzyme
complex between the drug's guanidinobenzoyl moiety and the
catalytic serine of TMPRSS2.
Although theMC state is not the main cause of inhibition, its
population directly translates into the potency of the inhibitor,
as higher MC population corresponds to a higher catalytic rate
and therefore yields a larger population of inhibited enzyme.
Consistently with the higher potency of nafamostat, it is found
to have a threefold more stable MC compared to camostat, and
sixfold compared to GBPA. A second contribution may be the
pKa of drug leaving groups, affecting the rate of enzyme
acylation.
Our detailed models of the thermodynamic and kinetics of
inhibitor binding highlight the bound state's heterogeneity,
with both drugs adopting multiple distinct poses. We note the
importance of residue Asp435 in the conserved S1-pocket,
which stabilizes the MC state and helps to orient the reactive
molecules in a conformation that is suited for catalysis. Nafa-
mostat has two groups that can potentially bind into the S1
pocket, whereas camostat has only one. However, we nd that
the population of S1 associated states are similar between
nafamostat, camostat, and GBPA, suggesting that non-covalent
inhibition is likely a minor contribution to the overall inhibi-
tion of TMPRSS2.
We conclude that the design of future TMPRSS2 inhibitors
with increased potency and specicity should incorporate the
following points:
First, stabilizing the non-covalent complex with the
TMPRSS2 active site is benecial for both, covalent and non-
covalent inhibitors. As S1 pocket binding is a major contribu-
tion to the stability of the non-covalent complex, effective drugs
may contain hydrogen bond donors and positively charged
moieties that could interact principally with Asp435, but also
with different backbone carbonyls of the loops that compose
the cavity (e.g. from Trp461 to Gly464).
Second, for covalent inhibitors, we must consider that the
catalytic serine is at a distance of around 1.3 nm from Asp435.
Thus, the reactive center of an effective drug and its S1-
interacting moieties should be within that distance. We note
that, even though all three molecules t well in the overall active988 | Chem. Sci., 2021, 12, 983–992site, the guanidinobenzoyl moiety is slightly shorter than the
ideal size of the TMPRSS2 cavity (Fig. S4†). We further suggest
that a drug should be size-compatible to the hydrophobic patch
on the S1 distal site (Fig. 3A and S4†). We speculate that drugs
with a large end to end distance and high rigidity may not t
well in the described TMPRSS2 scaffold, and in particular,
might be signicantly less reactive.
Third, optimizing the pKa of the drug's leaving group might
be benecial for improving covalent TMPRSS2 inhibitors. The
rst step of the reaction would be faster, and the acetyl–enzyme
intermediate would accumulate. We note that the deacetylation
off-rate must be very low, ideally on the order of magnitude of
guanidinobenzoyl moiety containing drugs.
Finally, we make our simulated equilibrium structures of
TMPRSS2 in complex with the simulated drugs available, hop-
ing they will be useful to guide future drug discovery efforts.4 Materials and methods
TMPRSS2 activity assays
The TMPRSS2 activity assay was described previously.31 Briey,
we transfected HEK-293T with a PLX304 plasmid containing the
open reading frame (ORF) sequence of TMPRSS2 which encodes
for the full length protein (492 amino acids). Control experi-
ments are conducted with PLX304 plasmids.
Eighteen hours later, we replaced the media to either PBS
alone or PBS in the presence of varying concentrations of
candidate inhibitors camostat and nafamostat. Fieen minutes
later, we added the uorogenic substrate BOC-QAR-AMC to the
wells to induce a measurable signal of enzyme activity. We
measured the uorescent signal immediately aer adding the
substrate, in 15 minutes intervals for a total time of 150
minutes.31 A baseline proteolytic activity of control cells was
measured; we hypothesize that this is because of proteolytic
cleavage of the substrate by endogenous transmembrane
proteases. However, the TMPRSS2 overexpression cells have
signicantly increased proteolytic activity compared with
control cells.31
To validate the exogenous expression of TMPRSS2, we per-
formed western-blot analysis of cell lysates from TMPRSS2
overexpressing cells and control cells. A 60 kDa band was
observed in TMPRSS2 overexpressing cells but not in control
cells, which is the expected molecular weight of TMPRSS2
protein aer post transcriptional modications, indicating that
the target protein has been successfully expressed.IC50 estimation
We used a generalized log-logistic dose–response model
f ðx; ðb; c; d; eÞÞ ¼ cþ d  c
1þ ebðlnðxÞlnðeÞÞ
with the concentration x, c and d representing the lower and
upper limits, b steepness of the curve, and e to estimate IC50
values.54
Upper and lower limits were set to themeans computed from
control experiments with no drug (upper limit) and PLX© 2021 The Author(s). Published by the Royal Society of Chemistry




















































View Article Onlineplasmid (no TMPRSS2; background noise). We used scipy's55
curve tting algorithms to extract the IC50 with error estimates.
Molecular dynamics simulations
MD simulations were run with OpenMM 7.4.0 (ref. 56) using the
CHARMM 36 force eld (2019 version).57 Camostat and nafa-
mostat structures were taken from PubChem58 with PubChem
CIDs 4413 (nafamostat) and 2536 (camostat), respectively, and
modeled with the CHARMM general force eld (CGenFF v.
4.3).59 We generated our MD setups with CharmmGUI.60 We
initiate a simulation box of side length 7.5 nm with a NaCl ion
concentration of 0.1 mol l1 at neutral charge and the TIP3P
water model.61 The setups contain 12038 (camostat), 12030
(GBPA), and 12039 (nafamostat) water molecules, respectively.
We run simulations in the NPT ensemble and keep the
temperature at 310 K (physiological temperature) and the
pressure at 1 bar. We use a Langevin integrator with 5 fs inte-
gration step and heavy hydrogen approximation (4 amu). PME
electrostatics, rigid water molecules, and a 1 nm cutoff for non-
bonded interactions are used. Simulation times vary between
100 and 500 ns and accumulate to 100 ms (camostat), 50 ms
(GBPA), 180 ms (nafamostat), respectively. Structures were
visualized using VMD.62
Due to the lack of a crystal structure for TMPRSS2, MD
simulations were seeded from a homology model. It is taken
from ref. 40, model 3W94 is chosen based on precursive MD
analyses that showed that 3W94 has the most stable catalytic
triad conguration (Fig. S1 and S2†). The construct includes
amino acids 256 to 491 of the full sequence, corresponding to
the catalytic chain except for a C-terminal Glycine missing due
to homology modeling against a shorter sequence. MD simu-
lations are seeded as follows: equilibrated docking poses
(highest scorers of ref. 40) of the ligand were generated in
a precursive run using another homology model. We note that
the used camostat docking pose resembles the one described by
ref. 63. This data set was equilibrated with local energy mini-
mization, 100 ps simulations with 2 fs time steps in NVT and
NPT ensemble subsequently. Frames are selected based on
a preliminary metastability analysis, protein conformation is
constraint to 3W94 homology model using a constraint force
minimizing minRMSD. Production run MD simulations are
started from these poses, i.e. from the same protein congura-
tion and with 77 (nafamostat) and 60 (camostat) ligand docking
poses, respectively. To ensure convergence of sampling statis-
tics, we ran multiple adaptive runs of simulations, seeding new
simulations with coordinates associated with sparsely sampled
states.
We later added the camostat metabolite GBPA by following
the same setup procedure. Due to its similarity to camostat, we
seeded production simulations from representative structures
of the camostat stage 1 Markov model (described below) using
200 representative structures.
Markov modeling
We model the binding and unbinding rates in a two step
procedure using Markov state type models.42–45,64–66 First, we© 2021 The Author(s). Published by the Royal Society of Chemistrydescribe drug unbound and associated states using a hidden
Markov model (HMM).67 Second, we dene a reactive state by
using distance cutoffs.
In detail, in the rst stage we dene distance features
between drug guanidinium group and TMPRSS2 Asp435
(minimal distance), drug amidinium group and TMPRSS2
Asp435 (minimal distance, nafamostat only). We further use
a binary “reactive” distance feature dened by drug ester carbon
to catalytic Ser441-OG, and catalytic serine (HG) to catalytic
histidine (NE2) and a threshold of 0.35 nm. If both last
mentioned distances are below the threshold, both nucleophilic
attack of the serine-OG to the drug ester group and proton
transfer from serine to histidine are possible, thus dening the
reactive state.
We discretize this space into 243 (camostat), 240 (GBPA), and
490 (nafamostat) states using regular spatial clustering and use
an HMM at lag time 5 ns with 5 (camostat, GBPA) or 8 (nafa-
mostat) hidden states. Nafamostat yields two metastable S1
associated states encoding for both binding directions,
camostat/GBPA a single one, that are dened by being at salt
bridge distance to Asp435. We note no signicant correlation
between the hidden states and the reactive state, i.e. reactivity is
not metastable. Also note that in contrast to later modeling
stages, reactivity according to this HMM does not necessitate S1
pocket binding. The described HMMs are used to generate the
(non-equilibrium) time series presented in Fig. 3G–I. Besides
distance to D435, we also show a reactivity coordinate which we
dene as the mean of (a) drug ester carbon to catalytic serine
oxygen and (b) catalytic serine hydrogen to catalytic histidine
nitrogen. Reactivity, i.e. when both reactive distances are within
range, is indicated with red markers (MC state).
In the second stage, we split the HMM bound states into
reactive and non-reactive by combining HMM Viterbi paths68
and the reactive state trajectories to one single discrete trajec-
tory consisting of 3 states. We dene the S1 associated states by
ltering the Viterbi paths of the HMM according to S1-
association. We use the reactivity trajectories to further bisect
the S1 associated state into reactive and non-reactive states,
yielding a three state discretization of the drug binding mode.
Note that the S1-reactive state is a subset of the reactive state in
the stage 1 HMM model.
We estimate a reversible maximum likelihood Markov state
model (MSM) from the stage 2 trajectories as described in ref.
45. We report the stationary probability vector as well as tran-
sition rates. The latter are approximated using the matrix
logarithm approximation of scipy55 to compute the transition
rate matrix R from the transition probability matrix T using the
denition T ¼ exp(Rs) with the lag time s. We found that all
reported quantities are converged with respect to the lag time
above s ¼ 500 ns which was thus chosen as the model lag time.
Errors are estimated by bootstrapping validation using
a random sample (with replacement) of the stage 2 trajectory
data. All MSM/HMM analyses were conducted using the
PyEMMA 2 soware (version 2.5.7).69
Dissociation constants Kd ¼ punbound/pbound from the non-
covalent state were estimated from this model and amount to
5.95 mM (4.60, 7.30) for camostat, 8.45 mM (5.81, 11.65) forChem. Sci., 2021, 12, 983–992 | 989




















































View Article OnlineGBPA, and 6.07 mM (5.55, 6.93) for nafamostat (68% condence
intervals).Kinetic model
Simplifying the binding kinetics into a three-state model
describing the binding to/dissociation from the Michaelis
complex (ligand concentration c and rates kon, koff), catalytic rate
of entering the covalent complex (kcat) and dissociation to the























The overall dissociation constant is then:
Kd ¼ p1





konðkdis þ kcatÞ (4)






ckon þ kcat (5)
The dissociation constant scales as:
Kd ¼ KMd
kdis
kcat þ kdis (6)
and thus the association constant scales with the stability of the
Michaelis complex by a constant factor given by the rates of




(7)Software and data availability
Structural ensembles of camostat, GBPA, and nafamostat
binding poses are published online at https://github.com/
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